Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alkermes plc ALKS

Healthcare Biotechnology
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products,... see more

Recent & Breaking News (NDAQ:ALKS)

Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

PR Newswire November 19, 2021

Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders

PR Newswire November 11, 2021

Alkermes to Take Part in the Stifel Virtual Healthcare Conference

PR Newswire November 9, 2021

Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica

PR Newswire November 8, 2021

Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

PR Newswire November 3, 2021

Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences

PR Newswire October 29, 2021

Alkermes plc Reports Third Quarter 2021 Financial Results

PR Newswire October 27, 2021

Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

PR Newswire October 26, 2021

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer

PR Newswire October 25, 2021

Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021

PR Newswire October 20, 2021

Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder

PR Newswire October 18, 2021

Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference

PR Newswire September 22, 2021

New Survey Provides Insights Into Drinking Behaviors During the Pandemic

PR Newswire September 22, 2021

Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress

PR Newswire September 13, 2021

Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program

PR Newswire September 9, 2021

Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference

PR Newswire September 2, 2021

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

PR Newswire August 2, 2021

Alkermes plc Reports Second Quarter 2021 Financial Results

PR Newswire July 28, 2021

Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program

PR Newswire July 23, 2021

Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021

PR Newswire July 21, 2021